|
RU2019126483A
(ru)
|
2017-01-23 |
2021-02-24 |
Ридженерон Фармасьютикалз, Инк. |
Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
|
|
KR20190139869A
(ko)
|
2017-04-11 |
2019-12-18 |
리제너론 파마슈티칼스 인코포레이티드 |
하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
US20190098879A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
|
|
AU2018348195B2
(en)
|
2017-10-11 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
AU2019239971B2
(en)
|
2018-03-21 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
AU2019360270B2
(en)
|
2018-10-18 |
2025-08-07 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|
|
JP7631215B2
(ja)
*
|
2019-03-28 |
2025-02-18 |
インテリア セラピューティクス，インコーポレイテッド |
Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
MX2021015122A
(es)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Animales no humanos que comprenden un locus de albumina humanizado.
|
|
CN113906134B
(zh)
|
2019-06-14 |
2025-06-24 |
瑞泽恩制药公司 |
Tau蛋白病模型
|
|
WO2021026318A2
(en)
*
|
2019-08-06 |
2021-02-11 |
The Penn State Research Foundation |
Engineered crispr/cas9 systems for simultaneous long-term regulation of multiple targets
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
EP4438729A3
(en)
*
|
2019-12-09 |
2025-03-26 |
Caribou Biosciences, Inc. |
Crispr abasic restricted nucleotides and crispr accuracy via analogs
|
|
EP4073249A1
(en)
*
|
2019-12-11 |
2022-10-19 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
BR112022015380A2
(pt)
|
2020-02-07 |
2022-09-27 |
Intellia Therapeutics Inc |
Composições e métodos para edição de gene de calicreína (klkb1)
|
|
MX2022012683A
(es)
*
|
2020-04-09 |
2023-01-11 |
Verve Therapeutics Inc |
Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
|
|
CN115956120A
(zh)
*
|
2020-05-12 |
2023-04-11 |
马萨诸塞大学 |
用于crispr基因组编辑的修饰的指导rna
|
|
MX2023006878A
(es)
|
2020-12-11 |
2023-07-31 |
Intellia Therapeutics Inc |
Composiciones y métodos para reducir el mhc de clase ii en una célula.
|
|
IL303506A
(en)
|
2020-12-11 |
2023-08-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
WO2022140587A1
(en)
|
2020-12-23 |
2022-06-30 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
|
CR20230320A
(es)
|
2020-12-23 |
2023-10-23 |
Intellia Therapeutics Inc |
Composiciones y métodos para reducir los hla-a en una célula
|
|
EP4288089A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
|
EP4288525A1
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Natural killer cell receptor 2b4 compositions and methods for immunotherapy
|
|
CN117042793A
(zh)
|
2021-02-08 |
2023-11-10 |
因特利亚治疗公司 |
用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法
|
|
AU2022227650A1
(en)
*
|
2021-02-25 |
2023-10-12 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
JP2024534114A
(ja)
|
2021-08-24 |
2024-09-18 |
インテリア セラピューティクス，インコーポレイテッド |
細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法
|
|
JP2024540723A
(ja)
|
2021-11-03 |
2024-11-01 |
インテリア セラピューティクス，インコーポレーテッド |
免疫療法のためのｃｄ３８組成物及び方法
|
|
IL312507A
(en)
*
|
2021-11-03 |
2024-07-01 |
Intellia Therapeutics Inc |
Modified guide rnas for gene editing
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
WO2023185697A2
(en)
*
|
2022-03-29 |
2023-10-05 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of transthyretin amyloidosis
|
|
CN114574598B
(zh)
*
|
2022-04-02 |
2023-08-08 |
中国农业科学院北京畜牧兽医研究所 |
鉴定或辅助鉴定猪5/6肋眼肌面积的方法
|
|
KR20250037788A
(ko)
*
|
2022-06-15 |
2025-03-18 |
빔 테라퓨틱스, 인크. |
보체 활성화를 감소시키기 위한 조성물 및 방법
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
AU2023293131A1
(en)
|
2022-06-16 |
2024-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class i in a cell
|
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2024003810A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Geneditbio Limited |
Guide rna with chemical modifications
|
|
KR20250124819A
(ko)
|
2022-12-21 |
2025-08-20 |
인텔리아 테라퓨틱스, 인크. |
프로단백질 전환효소 서브틸리신 켁신 9(pcsk9) 편집을 위한 조성물 및 방법
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
TW202436622A
(zh)
|
2023-03-06 |
2024-09-16 |
美商英特利亞醫療公司 |
用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法
|
|
WO2024186971A1
(en)
|
2023-03-07 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Cish compositions and methods for immunotherapy
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
CN119265190A
(zh)
*
|
2023-07-06 |
2025-01-07 |
上海交通大学 |
一种靶向TTR的saCas9 sgRNA及其修饰方式
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038642A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying cd70
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025059328A1
(en)
*
|
2023-09-14 |
2025-03-20 |
Empirico Inc. |
Modified oligonucleotides
|
|
WO2025101994A2
(en)
|
2023-11-10 |
2025-05-15 |
Intellia Therapeutics, Inc. |
Compositions, methods, and systems for genomic editing
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025137439A2
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025184520A1
(en)
|
2024-02-29 |
2025-09-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for angiopoietin like 3 (angptl3) editing
|
|
CN117925623B
(zh)
*
|
2024-03-20 |
2024-06-07 |
北京引正基因科技有限公司 |
用于hao1基因编辑和治疗ph1的组合物
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2026006390A2
(en)
*
|
2024-06-26 |
2026-01-02 |
Intellia Therapeutics, Inc. |
Modified guide rnas for genome editing
|